Management of paronychia with pseudopyogenic granulomas secondary to epidermal growth factor receptor inhibitors: An assessment of topical timolol and the need for multiple medical and procedural therapies

J Am Acad Dermatol. 2021 Mar;84(3):806-808. doi: 10.1016/j.jaad.2020.06.010. Epub 2020 Jun 11.

Authors

Brianna Olamiju¹, Shaman Bhullar¹, Emily L Coleman¹, Jonathan S Leventhal²

Affiliations

¹ Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut.
² Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut. Electronic address: jonathan.leventhal@yale.edu.

PMID: 32526318
DOI: 10.1016/j.jaad.2020.06.010

No abstract available

Publication types

Letter

MeSH terms

Administration, Topical
Adrenergic beta-Antagonists / administration & dosage*
Aged
Angiolymphoid Hyperplasia with Eosinophilia / chemically induced
Angiolymphoid Hyperplasia with Eosinophilia / complications
Angiolymphoid Hyperplasia with Eosinophilia / diagnosis
Angiolymphoid Hyperplasia with Eosinophilia / therapy*
Anti-Bacterial Agents / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Combined Modality Therapy / methods
Cryotherapy / methods
ErbB Receptors / antagonists & inhibitors
Female
Head and Neck Neoplasms / drug therapy
Humans
Lung Neoplasms / drug therapy
Male
Middle Aged
Paronychia / chemically induced
Paronychia / complications
Paronychia / diagnosis
Paronychia / therapy*
Protein Kinase Inhibitors / adverse effects
Retrospective Studies
Severity of Illness Index
Silver Nitrate / administration & dosage
Timolol / administration & dosage*
Treatment Outcome

Substances

Adrenergic beta-Antagonists
Anti-Bacterial Agents
Protein Kinase Inhibitors
Timolol
Silver Nitrate
EGFR protein, human
ErbB Receptors